Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios rubio s.a. - metilfenidato hidrocloruro - metilfenidato hidrocloruro....10 mg

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

laboratorios rubió; s.a., spain - calcium polystyrene sulfonate - powder for oral/rectal suspension - 99.75 %

Saudi Arabia - English - SFDA (Saudi Food and Drug Authority)- الهيئة العامة للغذاء والدواء

laboratorios rubió; s.a., spain - calcium polystyrene sulfonate - powder for oral suspension - 99.75 %

Panama - English - Ministerio de Salud (Dirección Nacional de Farmacia Y Drogas)

laboratorios rubio s.a. - hidralazina hidrocloruro - hidralazina hidrocloruro ....50.00 mg

United States - English - NLM (National Library of Medicine)

laboratorios rubio sa - cholestyramine (unii: 4b33bgi082) (cholestyramine - unii:4b33bgi082) - 1) cholestyramine for oral suspension usp, light is indicated as adjunctive therapy to diet for the reduction of elevated serum cholesterol in patients with primary hypercholesterolemia (elevated low density lipoprotein [ldl] cholesterol) who do not respond adequately to diet. cholestyramine for oral suspension usp, light may be useful to lower ldl cholesterol in patients who also have hypertriglyceridemia, but it is not indicated where hypertriglyceridemia is the abnormality of most concern. therapy with lipid-altering agents should be a component of multiple risk factor intervention in those individuals at significantly increased risk for atherosclerotic vascular disease due to hypercholesterolemia. treatment should begin and continue with dietary therapy specific for the type of hyperlipoproteinemia determined prior to initiation of drug therapy. excess body weight may be an important factor and caloric restriction for weight normalization should be addressed prior to drug therapy in the overweight. prior

Malta - English - Medicines Authority

laboratorios rubio s.a industria, 29, pol.ind. comte de sert, 08755 castellbisbal, barcelona, spain - colestyramine - powder for oral suspension - colestyramine 4 g - lipid modifying agents

Ireland - English - HPRA (Health Products Regulatory Authority)

laboratorios liconsa, s.a. - terbinafine - tablets - 250 milligram - antifungals for systemic use - antifungals for systemic use - it is indicated in the treatment of the following skin and nail fungal infections: treatment of tinea corporis, tinea cruris and tinea pedis, when oral therapy is considered appropriate depending on the site, severity or extent of the infection and for the treatment of onychomycosis caused by dermatophytes

European Union - English - EMA (European Medicines Agency)

laboratorios hipra s.a - live ge- tk- double-gene-deleted bovine herpes virus type 1, strain ceddel: 106.3–107.3 ccid50 - immunologicals - cattle - for the active immunisation of cattle from three months of age against bovine herpes virus type 1 (bohv-1) to reduce the clinical signs of infectious bovine rhinotracheitis (ibr) and field virus excretion.onset of immunity: 21 days after completion of the basic vaccination scheme.duration of immunity: 6 months after completion of the basic vaccination scheme

European Union - English - EMA (European Medicines Agency)

laboratorios hipra s.a. - inactivated bordetella bronchiseptica, strain 833cer / recombinant type-d pasteurella-multocida toxin (pmtr) - immunologicals - pigs (gilts and sows) - for the passive protection of piglets via colostrum after active immunisation of sows and gilts to reduce the clinical signs and lesions of progressive and non-progressive atrophic rhinitis, as well as to reduce weight loss associated with bordetella-bronchiseptica and pasteurella-multocida infections during the fattening period. challenge studies have demonstrated that passive immunity lasts until piglets are six weeks of age while in clinical field trials, the beneficial effects of vaccination (reduction in nasal lesion score and weight loss) are observed until slaughter.

European Union - English - EMA (European Medicines Agency)

laboratorios hipra s.a. - escherichia coli j5 inactivated, staphylococcus aureus (cp8) strain sp 140 inactivated, expressing slime-associated antigenic complex - immunologicals for bovidae - cattle (cows and heifers) - for herd immunisation of healthy cows and heifers, in dairy cattle herds with recurring mastitis problems, to reduce the incidence of sub-clinical mastitis and the incidence and the severity of the clinical signs of clinical mastitis caused by staphylococcus aureus, coliforms and coagulase-negative staphylococci.the full immunisation scheme induces immunity from approximately day 13 after the first injection until approximately day 78 after the third injection (equivalent to 130 days post-parturition).